Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. More than 30% patients present with metastases at diagnoses and will require systemic chemotherapy. In recent years many anti-EGFR targets have been developed. Among them, panitumumab, a fully human IgG2 monoclonal antibody has shown important benefits in the treatment of this disease.

• Publication year

  2012

• Venue

  Clinical Medicine Insights: Oncology

• Publication date

  2012-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4137/CMO.S5055PMID 22408376PMCID 3296490
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

  2023cited by this paper
• Novel Therapies for the Treatment of Small-Cell Lung Cancer

  2012cited by this paper
• Metastatic Colorectal Cancer

  2012cited by this paper
• Panitumumab in the Treatment of Metastatic Colorectal Cancer

  2012cited by this paper
• Panitumumab

  2012cited by this paper
• An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.

  2011cited by this paper
• Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

  2010cited by this paper
• Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

  2010cited by this paper
• Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.

  2010cited by this paper
• Metastatic Colorectal Cancer: Focus on Panitumumab

  2010cited by this paper
• 6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)

  2009cited by this paper
• Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors

  2009cited by this paper
• A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

  2009cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

  2009cited by this paper
• 6077 A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status

  2009cited by this paper
• Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

  2008cited by this paper
• KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

  2008cited by this paper
• Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies

  2008cited by this paper
• An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

  2008cited by this paper
• Determinants of RASistance to anti-epidermal growth factor receptor agents.

  2008cited by this paper
• EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

  2008cited by this paper
• Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.

  2007cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

  2007cited by this paper
• Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies

  2005cited by this paper
• Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

  2005cited by this paper
• Flexible dosing schedules of panitumumab (ABX-EGF) in cancer patients

  2005cited by this paper
• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  2005cited by this paper
• United States Food and Drug Administration Drug Approval Summary

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Targeting RAS signalling pathways in cancer therapy

  2003cited by this paper
• Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases.

  2002cited by this paper
• Optimal dosing of ABX-EGF in cancer patients

  2002cited by this paper
• Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.

  2001cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Expression of the Tyrosine Kinase Activity Growth Factor Receptors (EGFR, ERB B2, ERB B3) in Colorectal Adenocarcinomas and Adenomas

  2000cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper

• Synthesis of some new pyrimidine-based pyrene/benzochromene hybrids as EGFR kinase inhibitors in HCT-116 cancer cells through apoptosis

  2025cites this paper
• Long-Term Survivors of Metastatic Colorectal Cancer: A Tertiary Care Centre Experience

  2021cites this paper
• Phase I and II trial on infusional 5-fluorouracil and gefitinib in combination with preoperative radiotherapy in rectal cancer: 10-years median follow-up

  2018cites this paper